Pharmalicensing.com: Reports database: Report searching

Latest: Watch here for details of new products and services.

About Us: Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd

Report search

GlaxoSmithKline: Prospects to 2010

Espicom Healthcare Intelligence - 10/31/2006

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Headquartered in the UK and with operations based in the US, GSK is one of the leading ethical pharmaceutical companies in the industry with an estimated seven per cent share of the world's pharmaceutical market. GlaxoSmithKline was formed in 2000 as a result of the merger of Glaxo Wellcome and SmithKline Beecham. In 2005, it was the world's second largest research-based pharmaceutical company based on pharmaceutical sales.

GSK employs over 100,000 people in 116 countries, with over 40,000 of these in sales and marketing, the largest sales force in the industry. GSK has a broad portfolio, with projects in the fields of respiratory, central nervous system, anti-infectives, metabolic disorders, oncology, cardiovascular and urogenital. In addition, GSK has an extensive vaccines portfolio. According to GSK, it supplied one quarter of the world's vaccines and by the end of 2005 and had a further 25 in clinical development. The company has a leading position in genomics/genetics and new drug discovery technologies. GSK also has a Consumer Healthcare portfolio comprising over-the-counter medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.

Current Growth Drivers

GSK's key growth drivers in 2005 were:

Advair which maintained its strong growth in the US and Europe with sales of £1,687 million and £1,033 million, respectively.

Flonase for perennial rhinitis also showed strong growth in the US.

Wellbutrin XL performed exceptionally well, helping to offset the decline in sales of the immediate-release products due to generic competition.

Antivirals grew by 10 per cent, with HIV products up by 2 per cent. Sales of Valtrex, for herpes, grew by 26 per cent driven by patients switching to suppression therapy.

Sales of Avandia/Avandamet increased by 14 per cent, whilst antibacterial sales declined by 27 per cent as a result of generic competition that began in the third quarter 2002. Coreg sales increased by 33 per cent to £568 million reflecting the benefit of its wide range of indications.

Vaccines also performed well in 2005, growing by 26 per cent, reflecting a strong performance of Pediarix and Fluarix.

Latest Results
EXECUTIVE SUMMARY: Introduction; Financial Performance 2005; Company Strategy; Product/R&D Overview; Conclusion/Outlook
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT: Respiratory - Products; Respiratory - R&D; Respiratory - Summary; Neurosciences - Products; Neurosciences - R&D; Neurosciences - Summary; Infectious Diseases - Products; Infectious Diseases - R&D; Infectious Diseases - Summary; Cardiovascular - Products; Cardiovascular - R&D; Cardiovascular- Summary; Urologenital - Products; Urogenital - R&D; Urogenital - Summary; Musculoskeletal & Inflammation - R&D; Musculoskeletal & Inflammation - Summary; Metabolic - Products; Metabolic - R&D; Metabolic - Summary; Gastrointestinal - Products; Gastrointestinal - Summary; Oncology - Products; Oncology - R&D; Oncology - Summary; Vaccines - Products; Paediatric Vaccines - Products; Vaccines - R&D; Paediatric Vaccines - R&D; Pharmaccines - R&D; Vaccines - Summary
APPENDIX 1 - FINANCIAL PERFORMANCE: Full Year Results 2005
APPENDIX 2 - KEY AGREEMENTS: Adherex Technologies Inc; Adolor Corporation; Aeras Global TB Vaccine Foundation; Antigenics Inc; Aphton Corporation; Asahi Chemical Industry Co; Astellas Pharma; AVANT Immunotherapeutics Inc; Bavarian Nordic; Bayer; bioMérieux-Pierre Fabre; Bioseek Inc; Biovail Corporation International; Boehringer Ingelheim; Bristol-Myers Squibb; ChemoCentryx; Crucell NV/Walter Reed Army Institute of Research; Cytokinetics Inc; Daiichi Sankyo; Dainippon Sumitomo Pharma; Exelixis Inc; Galapagos nv; Genstruct Inc; Human Genome Sciences Inc (HGS); Institut Pasteur; Japan Tobacco (JT); Kissei Pharmaceutical; Ludwig Institute for Cancer Research (LICR); MedImmune Inc/Aviron Inc; Merck & Co; Millennium Pharmaceuticals Inc; Neurocrine Biosciences Inc; NeuroSearch A/S; NiKem Research srl; Novo Nordisk; Organon; Pharmacopeia Inc; Pozen Inc; Ranbaxy Laboratories Limited; Roche; Shionogi; Sirna Therapeutics Inc; SkyePharma PLC; Taiho Pharmaceutical Company Ltd; Tanabe; Teva Pharmaceutical Industries Ltd; The International AIDS Vaccine Initiative (IAVI) 238; The Malaria Vaccine Initiative (MVI) at Program for; The Wellcome Trust / Institute of Cancer Research; Theravance Inc; Unigene Laboratories Inc; University of California, San Francisco (UCSF)/Medicines for Malaria Venture (MMV); Vertex Pharmaceuticals Inc; Vitae Pharmaceuticals Inc; World Health Organization (WHO)
APPENDIX 3 - INFRASTRUCTURE: Research and Development Facilities; Manufacturing Facilities/Supply Chain
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES: Subsidiaries; Joint Ventures
APPENDIX 5 - PRODUCT INDEX
INDEX OF TABLES: Principal Operating Results; Operating Income By Business Area; Capital Expenditure By Business Area; Capital Expenditure By Geographic Area; Research & Development Expenditure By Business Area; Sales By Business Area; Sales By Therapeutic Area; Sales By Destination; Total Assets By Geographical Area; Employees By Geographical Area; Employees By Function; Recent Product Launches; Recent Product Approvals; Key R&D Projects; Major Products, Therapeutic Areas And Sales; R&D Pipeline; Sales Of Major Respiratory Products; Major Launched Products; Sales Of Major CNS Disorder Products; Major launched products; Sales Of Major Antiviral Products; Sales Of Major Antibacterial Products; Major launched products; Sales Of Cardiovascular And Urogenital Products; Major launched products; Major launched products; Sales Of Major Metabolic Products; Sales Of Major Oncology Products; Major launched products; Sales Of Major Vaccines; Major launched products
INDEX OF CHARTS: Sales, Costs and Operating Income; Operating Income By Business Area, 2005; Capital Expenditure By Geographic Area, 2005; Capital Expenditure By Geographic Area, 2004; R&D Expenditure By Business Area; Sales By Business Area; Breakdown Of Sales By Therapeutic Area, 2005; Sales of Top 5 Therapeutic Areas; Sales By Destination, 2005; Total Assets By Geographical Area; Employees By Geographical Area, 2005; Employees By Function; Employees and Productivity; Sales Of Current Top 10 Products (2000A-2010E); Top Selling Products, 2005; Sales Of Major Respiratory Products, 2005; Flixonase/Flonase Sales (2000A-2010E); Flixotide/Flovent Sales (2000A-2010E); Seretide Sales (2000A-2010E); Serevent Sales (2000A-2010E); Sales Of Major CNS Disorder Products, 2005; Imigran/Imitrex Sales (2000A-2010E); Lamictal Sales (2000A-2010E); ReQuip/Adartel Sales (2000A-2010E); Seroxat/Paxil Sales (2000A-2010E); Wellbutrin Sales (2000A-2010E); Zyban Sales (2000A-2010E); Sales Of Major Antiviral Products, 2005; Sales Of Major Antibacterial Products, 2005; Agenerase Sales (2000A-2010E); Augmentin Sales (2000A-2010E); Combivir Sales (2000A-2010E); Epivir Sales (2000A-2010E); Retrovir Sales (2000A-2010E); Trizivir Sales (2000A-2010E); Valtrex/Zelitrex Sales (2000A-2010E); Zeffix Sales (2000A-2010E); Ziagen Sales (2000A-2010E); Zinnat Sales (2000A-2010E); Zovirax Sales (2000A-2010E); Sales Of Cardiovascular And Urogenital Products, 2005; Coreg Sales (2000A-2010E); Avolve/Avodart Sales (2000A-2010E); Sales Of Major Metabolic Products, 2005; Avandia/Avandamet Sales (2000A-2010E); Zantac Sales (2000A-2010E); Sales Of Major Oncology Products; Hycamtin Sales (2000A-2010E); Zofran Sales (2000A-2010E); Sales Of Major Vaccines, 2005; Infanrix Sales (2000A-2010E); Sales, Costs and Operating Income; Profitability and Research Ratios; R&D Expenditure and Capital Expenditure; Current Assets, Liabilities and Ratio; Assets, Cash and Liquidity; Employees and Productivity

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Pharmalicensing current industry press releases.

Products:	Partnering Search	Pay-per-Click	Company Profiling	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us